Alaunos Therapeutics, Inc. (TCRT) 10-Year Financial Performance & Capital Metrics

TCRT • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutAlaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.Show more

Revenue $10K +100.0%
EBITDA -$5M +84.9%
Net Income -$5M +86.7%
EPS (Diluted) -2.92 +86.7%
Gross Margin 100% +100.1%
EBITDA Margin -48100% +92.5%
Operating Margin -48120% +93.0%
Net Margin -46790% +93.3%
ROE -111.8% +28.6%
ROIC -593.1% -128.6%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-38.87%

5Y-

3Y-70.71%

TTM0%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM65.83%

EPS CAGR

10Y-

5Y-

3Y-

TTM68.61%

ROCE

10Y Avg-94.12%

5Y Avg-93.17%

3Y Avg-106.42%

Latest-114.98%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	4.33M	6.86M	6.39M	146K	0	0	398K	2.92M	5K	10K
Revenue Growth %	2.16%	0.58%	-0.07%	-0.98%	-1%	-	-	6.34%	-1%	1%
Cost of Goods Sold+	0	0	0	0	629K	1.13M	0	0	4.8M	0
COGS % of Revenue	-	-	-	-	-	-	-	-	960.6%	-
Gross Profit+	4.33M	6.86M	6.39M	146K	-629K	-1.13M	398K	2.92M	-4.8M	10K
Gross Margin %	1%	1%	1%	1%	-	-	1%	1%	-959.6%	1%
Gross Profit Growth %	2.16%	0.58%	-0.07%	-0.98%	-5.31%	-0.79%	1.35%	6.34%	-2.64%	1%
Operating Expenses+	124.43M	172.17M	59.88M	54.05M	57.23M	79.23M	77.95M	38.03M	29.47M	4.82M
OpEx % of Revenue	28.72%	25.09%	9.37%	370.22%	-	-	195.85%	13.01%	5893.8%	482.2%
Selling, General & Admin	17.65M	14.38M	14.8M	19.92M	18.9M	26.54M	27.56M	13.14M	12.22M	4.46M
SG&A % of Revenue	4.07%	2.1%	2.32%	136.42%	-	-	69.26%	4.5%	2443.8%	446%
Research & Development	106.78M	157.79M	45.08M	34.13M	38.33M	52.7M	49.64M	25.02M	16.28M	362K
R&D % of Revenue	24.65%	23%	7.06%	233.79%	-	-	124.73%	8.56%	3255.8%	36.2%
Other Operating Expenses	12K	134K	465K	0	0	0	740K	-133K	971K	0
Operating Income+	-120.1M	-165.31M	-53.49M	-53.91M	-57.86M	-80.36M	-77.55M	-35.1M	-34.27M	-4.81M
Operating Margin %	-27.72%	-24.09%	-8.37%	-369.22%	-	-	-194.85%	-12.01%	-6853.4%	-481.2%
Operating Income Growth %	-1.76%	-0.38%	0.68%	-0.01%	-0.07%	-0.39%	0.03%	0.55%	0.02%	0.86%
EBITDA+	-119.74M	-165.02M	-53.12M	-53.33M	-57.23M	-79.23M	-74.95M	-32.35M	-31.95M	-4.81M
EBITDA Margin %	-27.64%	-24.05%	-8.31%	-365.29%	-	-	-188.32%	-11.07%	-6390.4%	-481%
EBITDA Growth %	-1.78%	-0.38%	0.68%	-0%	-0.07%	-0.38%	0.05%	0.57%	0.01%	0.85%
D&A (Non-Cash Add-back)	357K	290K	369K	573K	629K	1.13M	2.6M	2.76M	2.31M	2K
EBIT	-120.1M	-165.31M	-53.49M	-53.91M	-117.8M	-79.98M	-77.56M	-34.58M	-33.22M	-4.68M
Net Interest Income+	0	0	0	0	0	0	-1.19M	-3.15M	-1.92M	0
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	0	0	830K	0	0	0	1.19M	3.15M	1.92M	0
Other Income/Expense	12K	10K	-830K	789K	-59.94M	385K	-1.2M	-2.63M	-873K	133K
Pretax Income+	-120.09M	-165.3M	-54.32M	-53.12M	-117.8M	-79.98M	-78.75M	-37.73M	-35.14M	-4.68M
Pretax Margin %	-27.72%	-24.09%	-8.5%	-363.82%	-	-	-197.87%	-12.91%	-7028%	-467.9%
Income Tax+	-12K	114K	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-120.09M	-165.3M	-54.32M	-53.12M	-117.8M	-79.98M	-78.75M	-37.73M	-35.14M	-4.68M
Net Margin %	-27.72%	-24.09%	-8.5%	-363.82%	-	-	-197.87%	-12.91%	-7028%	-467.9%
Net Income Growth %	-2.78%	-0.38%	0.67%	0.02%	-1.22%	0.32%	0.02%	0.52%	0.07%	0.87%
Net Income (Continuing)	-120.09M	-165.3M	-54.32M	-53.12M	-117.8M	-79.98M	-78.75M	-37.73M	-35.14M	-4.68M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-143.63	-190.15	-59.50	-55.44	-158.90	-56.42	-53.80	-25.97	-21.97	-2.92
EPS Growth %	-2.05%	-0.32%	0.69%	0.07%	-1.87%	0.64%	0.05%	0.52%	0.15%	0.87%
EPS (Basic)	-143.63	-190.15	-59.50	-55.52	-158.90	-56.42	-53.80	-25.97	-21.97	-2.92
Diluted Shares Outstanding	836.11K	869.28K	912.92K	956.72K	1.12M	1.4M	1.43M	1.45M	1.6M	1.6M
Basic Shares Outstanding	836.11K	869.28K	912.92K	956.72K	1.12M	1.4M	1.43M	1.45M	1.6M	1.6M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	152.52M	104.88M	90.78M	84.28M	105.49M	130.59M	78.83M	53.8M	8.26M	2.75M
Cash & Short-Term Investments	140.72M	81.05M	70.95M	61.73M	79.74M	115.07M	76.05M	39.06M	6.06M	1.09M
Cash Only	140.72M	81.05M	70.95M	61.73M	79.74M	115.07M	76.05M	39.06M	6.06M	1.09M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	446K	21K	19K	1.86M	3.33M	4.67M	1.11M	4K	1K	5K
Days Sales Outstanding	37.58	1.12	1.09	4.66K	-	-	1.02K	0.5	73	182.5
Inventory	0	0	0	0	0	0	0	13.94M	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	23.81M	0	20.69M	0	0	1.67M	799K	2.2M	1.66M
Total Non-Current Assets+	1.2M	1.46M	14.82M	10.77M	3.62M	15.76M	16.03M	11.14M	2K	0
Property, Plant & Equipment	581K	843K	1.21M	1.1M	3.38M	14.88M	15.36M	10.6M	2K	0
Fixed Asset Turnover	7.46x	8.14x	5.28x	0.13x	-	-	0.03x	0.28x	2.50x	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	620K	104K	105K	0	0	0	0	0	0
Other Non-Current Assets	622K	1K	13.51M	9.56M	240K	875K	673K	542K	0	0
Total Assets+	153.72M	106.35M	105.61M	95.05M	109.11M	146.34M	94.86M	64.94M	8.26M	2.75M
Asset Turnover	0.03x	0.06x	0.06x	0.00x	-	-	0.00x	0.04x	0.00x	0.00x
Asset Growth %	2.4%	-0.31%	-0.01%	-0.1%	0.15%	0.34%	-0.35%	-0.32%	-0.87%	-0.67%
Total Current Liabilities+	18.12M	15.81M	20.86M	9.48M	12.53M	18.37M	16.04M	24.17M	1.96M	692K
Accounts Payable	2.01M	156K	4.42M	707K	906K	960K	1.37M	1.39M	616K	516K
Days Payables Outstanding	-	-	-	-	525.74	310.64	-	-	46.81	-
Short-Term Debt	0	0	0	0	0	0	8.6M	17.32M	0	0
Deferred Revenue (Current)	1000K	1000K	1000K	13K	0	0	0	0	0	0
Other Current Liabilities	1.8M	1.6M	2.06M	6.63M	1.91M	13.28M	3.65M	3.74M	1.3M	0
Current Ratio	8.42x	6.63x	4.35x	8.89x	8.42x	7.11x	4.91x	2.23x	4.22x	3.98x
Quick Ratio	8.42x	6.63x	4.35x	8.89x	8.42x	7.11x	4.91x	1.65x	4.22x	3.98x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	48.23M	42.52M	37.56M	4K	1.58M	4M	20.77M	2.22M	0	0
Long-Term Debt	0	0	0	0	0	0	16.25M	0	0	0
Capital Lease Obligations	0	0	0	0	1.58M	4M	4.52M	2.19M	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	313K	988K	2.42M	0	0	0	-1K	28K	0	0
Total Liabilities	66.35M	183.65M	202.41M	9.49M	14.1M	22.36M	36.81M	26.38M	1.96M	692K
Total Debt+	0	0	0	0	2.35M	4.81M	30.09M	20.07M	0	0
Net Debt	-140.72M	-81.05M	-70.95M	-61.73M	-77.39M	-110.25M	-45.96M	-18.99M	-6.06M	-1.09M
Debt / Equity	-	-	-	-	0.02x	0.04x	0.52x	0.52x	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-64.45x	-	-	-	-65.22x	-11.13x	-17.84x	-
Total Equity+	87.37M	-77.3M	-96.81M	85.56M	95.01M	123.98M	58.06M	38.55M	6.31M	2.06M
Equity Growth %	1.58%	-1.88%	-0.25%	1.88%	0.11%	0.3%	-0.53%	-0.34%	-0.84%	-0.67%
Book Value per Share	104.50	-88.92	-106.04	89.43	84.85	88.71	40.62	26.63	3.94	1.29
Total Shareholders' Equity	87.37M	-77.3M	-96.81M	85.56M	95.01M	123.98M	58.06M	38.55M	6.31M	2.06M
Common Stock	132K	132K	143K	161K	182K	215K	216K	240K	16K	2K
Retained Earnings	-492.7M	-658M	-712.44M	-566.33M	-684.13M	-764.1M	-842.85M	-880.63M	-915.77M	-920.45M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	-125.32M	-143.99M	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-10K	-58.33M	-54.67M	-49.46M	-40.85M	-57.01M	-61.47M	-29.23M	-30.14M	-4.97M
Operating CF Margin %	-0%	-8.5%	-8.56%	-338.75%	-	-	-154.44%	-10%	-6028.4%	-497.1%
Operating CF Growth %	1%	-5831.5%	0.06%	0.1%	0.17%	-0.4%	-0.08%	0.52%	-0.03%	0.84%
Net Income	-120.09M	-165.3M	-54.32M	-53.12M	-117.8M	-79.98M	-78.75M	-37.73M	-35.14M	-4.68M
Depreciation & Amortization	357K	290K	369K	575K	629K	1.13M	2.6M	2.76M	2.31M	2K
Stock-Based Compensation	8M	8.45M	8.45M	7.53M	7.34M	6.83M	10.77M	3.53M	2.8M	435K
Deferred Taxes	0	124K	0	0	0	0	0	0	0	0
Other Non-Cash Items	67.28M	119.02M	1.29M	-158K	60.75M	0	771K	1.34M	6.14M	0
Working Capital Changes	44.44M	-20.92M	-10.46M	-4.29M	8.22M	15.01M	3.14M	870K	-6.25M	-729K
Change in Receivables	-301K	425K	2K	-1.84M	-1.47M	-1.33M	3.56M	1.11M	3K	-4K
Change in Inventory	-8.49M	-12.25M	0	1.53M	1.47M	0	0	0	0	0
Change in Payables	4K	-1.85M	4.26M	-3.71M	199K	54K	274K	-25K	-773K	-100K
Cash from Investing+	-412K	-551K	-737K	-459K	-284K	-9.78M	-3.32M	-193K	1.35M	0
Capital Expenditures	-412K	-551K	-737K	-459K	-284K	-9.78M	-3.32M	-216K	-197K	0
CapEx % of Revenue	0.1%	0.08%	0.12%	3.14%	-	-	8.35%	0.07%	39.4%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	-737K	0	0	0	0	23K	1.54M	0
Cash from Financing+	98.34M	-788K	45.3M	40.31M	59.15M	102.12M	25.78M	6.37M	-18.14M	0
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	-7.12M	0	-17M	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	4.57M	7.84M	88K	11.83M	53.72M	442K	776K	21K	-125K	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-422K	-58.88M	-55.41M	-49.92M	-41.14M	-66.79M	-64.79M	-29.45M	-30.34M	-4.97M
FCF Margin %	-0.1%	-8.58%	-8.67%	-341.89%	-	-	-162.79%	-10.08%	-6067.8%	-497.1%
FCF Growth %	0.99%	-138.52%	0.06%	0.1%	0.18%	-0.62%	0.03%	0.55%	-0.03%	0.84%
FCF per Share	-0.50	-67.73	-60.69	-52.17	-36.74	-47.79	-45.33	-20.34	-18.97	-3.10
FCF Conversion (FCF/Net Income)	0.00x	0.35x	1.01x	0.93x	0.35x	0.71x	0.78x	0.77x	0.86x	1.06x
Interest Paid	0	0	0	0	0	0	630K	2.17M	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-198.15%	-3281.98%	-	-62.08%	-130.47%	-73.04%	-86.52%	-78.11%	-156.66%	-111.8%
Return on Invested Capital (ROIC)	-	-	-	-	-209.35%	-384.53%	-450.45%	-166.31%	-259.45%	-593.1%
Gross Margin	100%	100%	100%	100%	-	-	100%	100%	-95960%	100%
Net Margin	-2772.11%	-2409.23%	-850.26%	-36381.51%	-	-	-19786.68%	-1291.24%	-702800%	-46790%
Debt / Equity	-	-	-	-	0.02x	0.04x	0.52x	0.52x	-	-
Interest Coverage	-	-	-64.45x	-	-	-	-65.22x	-11.13x	-17.84x	-
FCF Conversion	0.00x	0.35x	1.01x	0.93x	0.35x	0.71x	0.78x	0.77x	0.86x	1.06x
Revenue Growth	215.51%	58.38%	-6.88%	-97.71%	-100%	-	-	634.17%	-99.83%	100%

Frequently Asked Questions

Growth & Financials

Alaunos Therapeutics, Inc. (TCRT) reported $0.0M in revenue for fiscal year 2024. This represents a 99% decrease from $0.7M in 2011.

Alaunos Therapeutics, Inc. (TCRT) grew revenue by 100.0% over the past year. This is strong growth.

Alaunos Therapeutics, Inc. (TCRT) reported a net loss of $4.0M for fiscal year 2024.

Dividend & Returns

Alaunos Therapeutics, Inc. (TCRT) has a return on equity (ROE) of -111.8%. Negative ROE indicates the company is unprofitable.

Alaunos Therapeutics, Inc. (TCRT) had negative free cash flow of $3.0M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Alaunos Therapeutics, Inc. (TCRT) 10-Year Financial Performance & Capital Metrics

TCRT • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

Revenue $10K +100.0%
EBITDA -$5M +84.9%
Net Income -$5M +86.7%
EPS (Diluted) -2.92 +86.7%
Gross Margin 100% +100.1%
EBITDA Margin -48100% +92.5%
Operating Margin -48120% +93.0%
Net Margin -46790% +93.3%
ROE -111.8% +28.6%
ROIC -593.1% -128.6%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-38.87%

5Y-

3Y-70.71%

TTM0%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM65.83%

EPS CAGR

10Y-

5Y-

3Y-

TTM68.61%

ROCE

10Y Avg-94.12%

5Y Avg-93.17%

3Y Avg-106.42%

Latest-114.98%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	4.33M	6.86M	6.39M	146K	0	0	398K	2.92M	5K	10K
Revenue Growth %	2.16%	0.58%	-0.07%	-0.98%	-1%	-	-	6.34%	-1%	1%
Cost of Goods Sold+	0	0	0	0	629K	1.13M	0	0	4.8M	0
COGS % of Revenue	-	-	-	-	-	-	-	-	960.6%	-
Gross Profit+	4.33M	6.86M	6.39M	146K	-629K	-1.13M	398K	2.92M	-4.8M	10K
Gross Margin %	1%	1%	1%	1%	-	-	1%	1%	-959.6%	1%
Gross Profit Growth %	2.16%	0.58%	-0.07%	-0.98%	-5.31%	-0.79%	1.35%	6.34%	-2.64%	1%
Operating Expenses+	124.43M	172.17M	59.88M	54.05M	57.23M	79.23M	77.95M	38.03M	29.47M	4.82M
OpEx % of Revenue	28.72%	25.09%	9.37%	370.22%	-	-	195.85%	13.01%	5893.8%	482.2%
Selling, General & Admin	17.65M	14.38M	14.8M	19.92M	18.9M	26.54M	27.56M	13.14M	12.22M	4.46M
SG&A % of Revenue	4.07%	2.1%	2.32%	136.42%	-	-	69.26%	4.5%	2443.8%	446%
Research & Development	106.78M	157.79M	45.08M	34.13M	38.33M	52.7M	49.64M	25.02M	16.28M	362K
R&D % of Revenue	24.65%	23%	7.06%	233.79%	-	-	124.73%	8.56%	3255.8%	36.2%
Other Operating Expenses	12K	134K	465K	0	0	0	740K	-133K	971K	0
Operating Income+	-120.1M	-165.31M	-53.49M	-53.91M	-57.86M	-80.36M	-77.55M	-35.1M	-34.27M	-4.81M
Operating Margin %	-27.72%	-24.09%	-8.37%	-369.22%	-	-	-194.85%	-12.01%	-6853.4%	-481.2%
Operating Income Growth %	-1.76%	-0.38%	0.68%	-0.01%	-0.07%	-0.39%	0.03%	0.55%	0.02%	0.86%
EBITDA+	-119.74M	-165.02M	-53.12M	-53.33M	-57.23M	-79.23M	-74.95M	-32.35M	-31.95M	-4.81M
EBITDA Margin %	-27.64%	-24.05%	-8.31%	-365.29%	-	-	-188.32%	-11.07%	-6390.4%	-481%
EBITDA Growth %	-1.78%	-0.38%	0.68%	-0%	-0.07%	-0.38%	0.05%	0.57%	0.01%	0.85%
D&A (Non-Cash Add-back)	357K	290K	369K	573K	629K	1.13M	2.6M	2.76M	2.31M	2K
EBIT	-120.1M	-165.31M	-53.49M	-53.91M	-117.8M	-79.98M	-77.56M	-34.58M	-33.22M	-4.68M
Net Interest Income+	0	0	0	0	0	0	-1.19M	-3.15M	-1.92M	0
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	0	0	830K	0	0	0	1.19M	3.15M	1.92M	0
Other Income/Expense	12K	10K	-830K	789K	-59.94M	385K	-1.2M	-2.63M	-873K	133K
Pretax Income+	-120.09M	-165.3M	-54.32M	-53.12M	-117.8M	-79.98M	-78.75M	-37.73M	-35.14M	-4.68M
Pretax Margin %	-27.72%	-24.09%	-8.5%	-363.82%	-	-	-197.87%	-12.91%	-7028%	-467.9%
Income Tax+	-12K	114K	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-120.09M	-165.3M	-54.32M	-53.12M	-117.8M	-79.98M	-78.75M	-37.73M	-35.14M	-4.68M
Net Margin %	-27.72%	-24.09%	-8.5%	-363.82%	-	-	-197.87%	-12.91%	-7028%	-467.9%
Net Income Growth %	-2.78%	-0.38%	0.67%	0.02%	-1.22%	0.32%	0.02%	0.52%	0.07%	0.87%
Net Income (Continuing)	-120.09M	-165.3M	-54.32M	-53.12M	-117.8M	-79.98M	-78.75M	-37.73M	-35.14M	-4.68M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-143.63	-190.15	-59.50	-55.44	-158.90	-56.42	-53.80	-25.97	-21.97	-2.92
EPS Growth %	-2.05%	-0.32%	0.69%	0.07%	-1.87%	0.64%	0.05%	0.52%	0.15%	0.87%
EPS (Basic)	-143.63	-190.15	-59.50	-55.52	-158.90	-56.42	-53.80	-25.97	-21.97	-2.92
Diluted Shares Outstanding	836.11K	869.28K	912.92K	956.72K	1.12M	1.4M	1.43M	1.45M	1.6M	1.6M
Basic Shares Outstanding	836.11K	869.28K	912.92K	956.72K	1.12M	1.4M	1.43M	1.45M	1.6M	1.6M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	152.52M	104.88M	90.78M	84.28M	105.49M	130.59M	78.83M	53.8M	8.26M	2.75M
Cash & Short-Term Investments	140.72M	81.05M	70.95M	61.73M	79.74M	115.07M	76.05M	39.06M	6.06M	1.09M
Cash Only	140.72M	81.05M	70.95M	61.73M	79.74M	115.07M	76.05M	39.06M	6.06M	1.09M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	446K	21K	19K	1.86M	3.33M	4.67M	1.11M	4K	1K	5K
Days Sales Outstanding	37.58	1.12	1.09	4.66K	-	-	1.02K	0.5	73	182.5
Inventory	0	0	0	0	0	0	0	13.94M	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	23.81M	0	20.69M	0	0	1.67M	799K	2.2M	1.66M
Total Non-Current Assets+	1.2M	1.46M	14.82M	10.77M	3.62M	15.76M	16.03M	11.14M	2K	0
Property, Plant & Equipment	581K	843K	1.21M	1.1M	3.38M	14.88M	15.36M	10.6M	2K	0
Fixed Asset Turnover	7.46x	8.14x	5.28x	0.13x	-	-	0.03x	0.28x	2.50x	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	620K	104K	105K	0	0	0	0	0	0
Other Non-Current Assets	622K	1K	13.51M	9.56M	240K	875K	673K	542K	0	0
Total Assets+	153.72M	106.35M	105.61M	95.05M	109.11M	146.34M	94.86M	64.94M	8.26M	2.75M
Asset Turnover	0.03x	0.06x	0.06x	0.00x	-	-	0.00x	0.04x	0.00x	0.00x
Asset Growth %	2.4%	-0.31%	-0.01%	-0.1%	0.15%	0.34%	-0.35%	-0.32%	-0.87%	-0.67%
Total Current Liabilities+	18.12M	15.81M	20.86M	9.48M	12.53M	18.37M	16.04M	24.17M	1.96M	692K
Accounts Payable	2.01M	156K	4.42M	707K	906K	960K	1.37M	1.39M	616K	516K
Days Payables Outstanding	-	-	-	-	525.74	310.64	-	-	46.81	-
Short-Term Debt	0	0	0	0	0	0	8.6M	17.32M	0	0
Deferred Revenue (Current)	1000K	1000K	1000K	13K	0	0	0	0	0	0
Other Current Liabilities	1.8M	1.6M	2.06M	6.63M	1.91M	13.28M	3.65M	3.74M	1.3M	0
Current Ratio	8.42x	6.63x	4.35x	8.89x	8.42x	7.11x	4.91x	2.23x	4.22x	3.98x
Quick Ratio	8.42x	6.63x	4.35x	8.89x	8.42x	7.11x	4.91x	1.65x	4.22x	3.98x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	48.23M	42.52M	37.56M	4K	1.58M	4M	20.77M	2.22M	0	0
Long-Term Debt	0	0	0	0	0	0	16.25M	0	0	0
Capital Lease Obligations	0	0	0	0	1.58M	4M	4.52M	2.19M	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	313K	988K	2.42M	0	0	0	-1K	28K	0	0
Total Liabilities	66.35M	183.65M	202.41M	9.49M	14.1M	22.36M	36.81M	26.38M	1.96M	692K
Total Debt+	0	0	0	0	2.35M	4.81M	30.09M	20.07M	0	0
Net Debt	-140.72M	-81.05M	-70.95M	-61.73M	-77.39M	-110.25M	-45.96M	-18.99M	-6.06M	-1.09M
Debt / Equity	-	-	-	-	0.02x	0.04x	0.52x	0.52x	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-64.45x	-	-	-	-65.22x	-11.13x	-17.84x	-
Total Equity+	87.37M	-77.3M	-96.81M	85.56M	95.01M	123.98M	58.06M	38.55M	6.31M	2.06M
Equity Growth %	1.58%	-1.88%	-0.25%	1.88%	0.11%	0.3%	-0.53%	-0.34%	-0.84%	-0.67%
Book Value per Share	104.50	-88.92	-106.04	89.43	84.85	88.71	40.62	26.63	3.94	1.29
Total Shareholders' Equity	87.37M	-77.3M	-96.81M	85.56M	95.01M	123.98M	58.06M	38.55M	6.31M	2.06M
Common Stock	132K	132K	143K	161K	182K	215K	216K	240K	16K	2K
Retained Earnings	-492.7M	-658M	-712.44M	-566.33M	-684.13M	-764.1M	-842.85M	-880.63M	-915.77M	-920.45M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	-125.32M	-143.99M	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-10K	-58.33M	-54.67M	-49.46M	-40.85M	-57.01M	-61.47M	-29.23M	-30.14M	-4.97M
Operating CF Margin %	-0%	-8.5%	-8.56%	-338.75%	-	-	-154.44%	-10%	-6028.4%	-497.1%
Operating CF Growth %	1%	-5831.5%	0.06%	0.1%	0.17%	-0.4%	-0.08%	0.52%	-0.03%	0.84%
Net Income	-120.09M	-165.3M	-54.32M	-53.12M	-117.8M	-79.98M	-78.75M	-37.73M	-35.14M	-4.68M
Depreciation & Amortization	357K	290K	369K	575K	629K	1.13M	2.6M	2.76M	2.31M	2K
Stock-Based Compensation	8M	8.45M	8.45M	7.53M	7.34M	6.83M	10.77M	3.53M	2.8M	435K
Deferred Taxes	0	124K	0	0	0	0	0	0	0	0
Other Non-Cash Items	67.28M	119.02M	1.29M	-158K	60.75M	0	771K	1.34M	6.14M	0
Working Capital Changes	44.44M	-20.92M	-10.46M	-4.29M	8.22M	15.01M	3.14M	870K	-6.25M	-729K
Change in Receivables	-301K	425K	2K	-1.84M	-1.47M	-1.33M	3.56M	1.11M	3K	-4K
Change in Inventory	-8.49M	-12.25M	0	1.53M	1.47M	0	0	0	0	0
Change in Payables	4K	-1.85M	4.26M	-3.71M	199K	54K	274K	-25K	-773K	-100K
Cash from Investing+	-412K	-551K	-737K	-459K	-284K	-9.78M	-3.32M	-193K	1.35M	0
Capital Expenditures	-412K	-551K	-737K	-459K	-284K	-9.78M	-3.32M	-216K	-197K	0
CapEx % of Revenue	0.1%	0.08%	0.12%	3.14%	-	-	8.35%	0.07%	39.4%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	-737K	0	0	0	0	23K	1.54M	0
Cash from Financing+	98.34M	-788K	45.3M	40.31M	59.15M	102.12M	25.78M	6.37M	-18.14M	0
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	-7.12M	0	-17M	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	4.57M	7.84M	88K	11.83M	53.72M	442K	776K	21K	-125K	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-422K	-58.88M	-55.41M	-49.92M	-41.14M	-66.79M	-64.79M	-29.45M	-30.34M	-4.97M
FCF Margin %	-0.1%	-8.58%	-8.67%	-341.89%	-	-	-162.79%	-10.08%	-6067.8%	-497.1%
FCF Growth %	0.99%	-138.52%	0.06%	0.1%	0.18%	-0.62%	0.03%	0.55%	-0.03%	0.84%
FCF per Share	-0.50	-67.73	-60.69	-52.17	-36.74	-47.79	-45.33	-20.34	-18.97	-3.10
FCF Conversion (FCF/Net Income)	0.00x	0.35x	1.01x	0.93x	0.35x	0.71x	0.78x	0.77x	0.86x	1.06x
Interest Paid	0	0	0	0	0	0	630K	2.17M	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-198.15%	-3281.98%	-	-62.08%	-130.47%	-73.04%	-86.52%	-78.11%	-156.66%	-111.8%
Return on Invested Capital (ROIC)	-	-	-	-	-209.35%	-384.53%	-450.45%	-166.31%	-259.45%	-593.1%
Gross Margin	100%	100%	100%	100%	-	-	100%	100%	-95960%	100%
Net Margin	-2772.11%	-2409.23%	-850.26%	-36381.51%	-	-	-19786.68%	-1291.24%	-702800%	-46790%
Debt / Equity	-	-	-	-	0.02x	0.04x	0.52x	0.52x	-	-
Interest Coverage	-	-	-64.45x	-	-	-	-65.22x	-11.13x	-17.84x	-
FCF Conversion	0.00x	0.35x	1.01x	0.93x	0.35x	0.71x	0.78x	0.77x	0.86x	1.06x
Revenue Growth	215.51%	58.38%	-6.88%	-97.71%	-100%	-	-	634.17%	-99.83%	100%

Frequently Asked Questions

Growth & Financials

Alaunos Therapeutics, Inc. (TCRT) reported $0.0M in revenue for fiscal year 2024. This represents a 99% decrease from $0.7M in 2011.

Alaunos Therapeutics, Inc. (TCRT) grew revenue by 100.0% over the past year. This is strong growth.

Alaunos Therapeutics, Inc. (TCRT) reported a net loss of $4.0M for fiscal year 2024.

Dividend & Returns

Alaunos Therapeutics, Inc. (TCRT) has a return on equity (ROE) of -111.8%. Negative ROE indicates the company is unprofitable.

Alaunos Therapeutics, Inc. (TCRT) had negative free cash flow of $3.0M in fiscal year 2024, likely due to heavy capital investments.